Immuneering Corp

IMRX11 Dec 2024
Healthcare
$2.13
+0.01 (+1.40%)
Lowest Today
$2.06
Highest Today
$2.2
Today’s Open
$2.13
Prev. Close
$2.14
52 Week High
$8.41
52 Week Low
$1
BUY
SELL
To Invest in Immuneering Corp

Immuneering Corp

Healthcare
IMRX11 Dec 2024
₹
+0.01 (+1.40%)
1M
3M
6M
1Y
5Y
Low
$2.06
Day’s Range
High
$2.2
2.06
52 Week Low
$1
52-Week Range
52 Week High
$8.41
1
1 Day
-
1 Week
-5.86%
1 month return
+12.76%
3 month return
+67.82%
6 month return
+28.1%
1 Year return
-69%
3 Years return
-89.65%
5 Years return
-
10 Years return
-
Institutional Holdings
Vanguard Group Inc
3.45
T. Rowe Price Associates, Inc.
2.61
Vanguard Total Stock Mkt Idx Inv
2.37
BlackRock Inc
1.72
T. Rowe Price Health Sciences
1.64
Morgan Stanley - Brokerage Accounts
1.45
Vanguard Institutional Extnd Mkt Idx Tr
0.93

Market Status

Fundamentals
Market Cap
66.45 mln
PB Ratio
1.17
PE Ratio
0
Enterprise Value
21.27 mln
Total Assets
102.58 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Organisation
Immuneering Corp
Employees
66
Industry
Biotechnology
CEO
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Get expert assistance for portfolio management

BUY
SELL